Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995;35(3):254-6.
doi: 10.1007/BF00686557.

Effects of storage on the binding of carboplatin to plasma proteins

Affiliations

Effects of storage on the binding of carboplatin to plasma proteins

K Erkmen et al. Cancer Chemother Pharmacol. 1995.

Abstract

Plasma ultrafiltrates are routinely used in pharmacokinetic studies of carboplatin. Experiments were performed to detect and quantitate artifactual decreases in the platinum concentration of ultrafiltrates prepared from plasma samples stored at -20 degrees C and -70 degrees C. Carboplatin was added to anticoagulated, whole human blood to produce a 20 microgram/ml concentration. Plasma produced from the blood was stored frozen at either -20 degrees C or -70 degrees C. Aliquots from each storage condition were thawed and ultrafiltered once a week for up to 100 days. Platinum concentrations in ultrafiltrates and plasma were determined by flameless atomic absorption spectrometry. There was no loss of ultrafilterable platinum in plasma samples stored at -70 degrees C, whereas there was a steady decrease in free platinum concentration in ultrafiltrates prepared from plasma samples stored at -20 degrees C. These results imply that pharmacokinetic studies of carboplatin should use ultrafiltrates prepared immediately or that plasma for such studies should be stored at -70 degrees C. Storage of carboplatin-containing plasma at -20 degrees C and subsequent ultrafiltration is not acceptable, because measurement of platinum in such ultrafiltrates will be artifactually low.

PubMed Disclaimer

References

    1. Cancer Chemother Pharmacol. 1993;31(4):324-7 - PubMed
    1. Cancer Chemother Pharmacol. 1987;20(4):271-6 - PubMed
    1. Comput Programs Biomed. 1979 Mar;9(2):115-34 - PubMed
    1. Clin Pharmacokinet. 1991 Oct;21(4):242-61 - PubMed
    1. J Biol Chem. 1983 May 10;258(9):5764-9 - PubMed

Publication types

LinkOut - more resources